Accord BioPharma Secures FDA Approval for FILKRI™ (filgrastim-laha), Biosimilar to NEUPOGEN® Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., has announced a significant milestone: the U.S. Food and Drug Administration (FDA) has approved FILKRI™ (filgrastim-laha). This product is a biosimilar to the established reference product, NEUPOGEN® (filgrastim). The approval, announced on February 17,…